Datroway, datopotamab deruxtecan-dlnk
Named-patient access overview. Datroway is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
About Datroway
Datroway (datopotamab deruxtecan-dlnk) is co-developed by Daiichi Sankyo and AstraZeneca and was approved by the US FDA in 2025 for previously treated hormone receptor-positive, HER2-negative metastatic breast cancer, with a subsequent 2025 approval covering EGFR-mutated locally advanced or metastatic non-small cell lung cancer. It is an antibody-drug conjugate that uses a TROP2-directed monoclonal antibody to deliver a topoisomerase I inhibitor payload (deruxtecan, DXd) selectively to TROP2-expressing tumor cells.
Datroway is given as an intravenous infusion in an oncology infusion setting on a label-defined schedule, with pre-medication and routine monitoring for infusion reactions, stomatitis, ocular toxicity, and interstitial lung disease as set out in the prescribing information. International patients pursuing Datroway through cross-border channels typically access it via Named Patient Program or personal-import pathways, with the destination country's regulator and the patient's treating oncologist coordinating documentation and administration.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Datroway
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Datroway for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Datroway is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Datroway in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Datroway
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.